123 related articles for article (PubMed ID: 22940586)
81. Conditioned anti-immobility by ketamine: A comparison to escitalopram and bupropion.
Melanson B; Wolter M; Leatham Z; Lapointe T; Kennedy S; Leri F
Exp Clin Psychopharmacol; 2023 Apr; 31(2):350-361. PubMed ID: 35467924
[TBL] [Abstract][Full Text] [Related]
82. The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats.
Menezes CES; McIntyre RS; Chaves Filho AJM; Vasconcelos SMM; de Sousa FCF; Quevedo J; Hyphantis TN; Carvalho AF; Macêdo D
Pharmacol Rep; 2018 Dec; 70(6):1173-1179. PubMed ID: 30321807
[TBL] [Abstract][Full Text] [Related]
83. The effect of bupropion augmentation of minocycline in the treatment of depression.
Bendale M; DSouza SR; Addepalli V; Kale PP
Acta Neurobiol Exp (Wars); 2019; 79(2):217-224. PubMed ID: 31342957
[TBL] [Abstract][Full Text] [Related]
84. Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm.
Mitchell PJ; Fletcher A
Neuropharmacology; 1993 Oct; 32(10):1001-9. PubMed ID: 8295710
[TBL] [Abstract][Full Text] [Related]
85. Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.
Bender G; Gosset J; Florian J; Tan K; Field M; Marshall S; DeJongh J; Bies R; Danhof M
Pharm Res; 2009 Oct; 26(10):2259-69. PubMed ID: 19669867
[TBL] [Abstract][Full Text] [Related]
86. Oxytocin: a therapeutic target for mental disorders.
Matsuzaki M; Matsushita H; Tomizawa K; Matsui H
J Physiol Sci; 2012 Nov; 62(6):441-4. PubMed ID: 23007624
[TBL] [Abstract][Full Text] [Related]
87. The antidepressants venlafaxine ("Effexor") and fluoxetine ("Prozac") produce different effects on locomotion in two species of marine snail, the oyster drill (Urosalpinx cinerea) and the starsnail (Lithopoma americanum).
Fong PP; Bury TB; Dworkin-Brodsky AD; Jasion CM; Kell RC
Mar Environ Res; 2015 Feb; 103():89-94. PubMed ID: 25481651
[TBL] [Abstract][Full Text] [Related]
88. Effects of acute bupropion administration on locomotor activity in adolescent and adult mice.
Redolat R; Vidal J; Gómez MC; Carrasco MC
Behav Pharmacol; 2005 Feb; 16(1):59-62. PubMed ID: 15706139
[TBL] [Abstract][Full Text] [Related]
89. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n).
Mahesh R; Bhatt S; Devadoss T; Jindal A; Gautam B; Pandey D
J Young Pharm; 2012 Oct; 4(4):235-44. PubMed ID: 23493308
[TBL] [Abstract][Full Text] [Related]
90. Synergistic Action of Sodium Selenite with some Antidepressants and Diazepam in Mice.
Kędzierska E; Dąbkowska L; Obierzyński P; Polakowska M; Poleszak E; Wlaź P; Szewczyk K; Kotlińska J
Pharmaceutics; 2018 Dec; 10(4):. PubMed ID: 30545058
[TBL] [Abstract][Full Text] [Related]
91. Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano F; Chiappini S
Front Pharmacol; 2018; 9():239. PubMed ID: 29618978
[No Abstract] [Full Text] [Related]
92. A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression.
Mesripour A; Meshkati A; Hajhashemi V
Turk J Pharm Sci; 2020 Jun; 17(3):293-298. PubMed ID: 32636707
[TBL] [Abstract][Full Text] [Related]
93. Behavioral and neuronal biochemical possible effects in experimental induced chronic mild stress in male albino rats under the effect of oral barley administration in comparison to venlafaxine.
Darwish IE; Maklad HM; Diab IH
Int J Physiol Pathophysiol Pharmacol; 2013; 5(2):128-36. PubMed ID: 23750311
[TBL] [Abstract][Full Text] [Related]
94. Venlafaxine induced hypertension:a case report.
Pardal PK; John TR; Rathee SP
Indian J Psychiatry; 2001 Oct; 43(4):360-1. PubMed ID: 21407890
[TBL] [Abstract][Full Text] [Related]
95. Considerations of Pool Dimensions in the Forced Swim Test in Predicting the Potential Antidepressant Activity of Drugs.
Rosas-Sánchez GU; German-Ponciano LJ; Rodríguez-Landa JF
Front Behav Neurosci; 2021; 15():757348. PubMed ID: 35069137
[No Abstract] [Full Text] [Related]
96. The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment.
Hou YC; Lai CH
Clin Psychopharmacol Neurosci; 2015 Dec; 13(3):319-20. PubMed ID: 26598593
[TBL] [Abstract][Full Text] [Related]
97. Correction to Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
ACS Chem Neurosci; 2018 Jul; 9(7):1868. PubMed ID: 29897231
[No Abstract] [Full Text] [Related]
98. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.
Proft F; Kopf J; Olmes D; Hempel S; Schmidt B; Riederer P; Deckert J; Pfuhlmann B; Reif A; Unterecker S
Pharmacopsychiatry; 2015 Mar; 48(2):81. PubMed ID: 25738265
[No Abstract] [Full Text] [Related]
99. Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.
Coutens B; Yrondi A; Rampon C; Guiard BP
Psychopharmacology (Berl); 2022 Sep; 239(9):2735-2752. PubMed ID: 35947166
[TBL] [Abstract][Full Text] [Related]
100. Possible involvement of NO-cGMP signaling in the antidepressant like Effect of Amantadine in mice.
Maratha S; Sharma V; Walia V
Metab Brain Dis; 2022 Aug; 37(6):2067-2075. PubMed ID: 35666396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
